CN1720918A - 右美沙芬和异丙嗪的复方颗粒剂及其制备方法 - Google Patents
右美沙芬和异丙嗪的复方颗粒剂及其制备方法 Download PDFInfo
- Publication number
- CN1720918A CN1720918A CN 200410068920 CN200410068920A CN1720918A CN 1720918 A CN1720918 A CN 1720918A CN 200410068920 CN200410068920 CN 200410068920 CN 200410068920 A CN200410068920 A CN 200410068920A CN 1720918 A CN1720918 A CN 1720918A
- Authority
- CN
- China
- Prior art keywords
- promethazine
- adhesive
- dextromethorphan
- preparation
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 title claims abstract description 15
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title claims abstract description 15
- 229960001985 dextromethorphan Drugs 0.000 title claims abstract description 15
- 229960003910 promethazine Drugs 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims abstract description 6
- 239000002775 capsule Substances 0.000 title abstract description 6
- 239000008187 granular material Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 4
- 239000000853 adhesive Substances 0.000 claims description 14
- 230000001070 adhesive effect Effects 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 9
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000010265 sodium sulphite Nutrition 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229950005770 hyprolose Drugs 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229960002244 promethazine hydrochloride Drugs 0.000 abstract description 5
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 abstract description 5
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 239000007767 bonding agent Substances 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及医药用的右美沙芬和异丙嗪的复方颗粒剂及其制备方法。该颗粒剂每袋含有氢溴酸右美沙芬7.5～30mg、最好为14～16mg；含盐酸异丙嗪3.1～12.5mg、最好为5～7mg。还含有3～24％、最好为14～16％抗氧化稳定剂、黏合剂和90～97％、最好为94～95％矫味剂。特点是通过采用特殊的处方和制备方法，提高了药物的稳定性，从而保证了质量和疗效。
Description
技术领域 本发明涉及医药用的右美沙芬和异丙嗪的复方颗粒剂及其制备方法。
背景技术 右美沙芬是一有效的镇咳药物，除单方应用外多与其它解热镇痛药、抗组织胺药、祛痰药、血管收缩药等组合治疗感冒。异丙嗪具抗组织胺和镇静作用，与右美沙芬组合可以提高右美沙芬的镇咳效果，适用于治疗和缓解由感冒、急性或慢性支气管炎、支气管哮喘、咽喉炎、肺结核以及其他上呼吸道感染引发的咳嗽。
目前已上市的止咳药品很多，但有许多药物因某些原因并不够理想。如剂型是片剂或胶囊时，往往不适合儿童和吞咽困难的病人服用；剂型为糖浆剂或溶液剂时，又存在贮存、携带不便的问题，而且由于是糖浆剂或溶液剂，许多药物稳定性较差，如异丙嗪容易氧化而降低质量，这些都直接影响药物的疗效。
发明内容 本发明旨在克服已有止咳药稳定性差、不便于儿童和吞咽困难的病人应用的问题，保留了糖浆剂、溶液剂等液体剂型和片剂、胶囊剂、颗粒剂等固体剂型的各自的特点，制备了右美沙芬和异丙嗪的复方颗粒剂。通过采用特殊的处方和生产工艺，提高了产品的稳定性，从而保证了质量和疗效。其特点是：
(1)稳定性更好。由于颗粒剂始终处于干燥无水的状态，且包装严密，避免与空气接触，因而较糖浆剂、溶液剂等液体制剂更稳定。
(2)颗粒剂虽为固体制剂，但其在服用时加水冲服亦即组成了溶液剂，因而较片剂和胶囊吸收好、起效快、生物利用度高。
(3)适用人群更广。颗粒剂加水冲服时，形成类似溶液剂那样的清澈透明溶液，病人乐意接受，适合于2岁以上儿童和吞咽不便的病人服用。
(4)颗粒剂为单剂量包装，每次服用剂量较片剂、胶囊准确，而且不会像糖浆剂、溶液剂那样多次服用易造成污染，且病愈后剩余药品易于保管，日后还可应用。
(5)生产、运输、贮藏、携带和使用更方便。
本发明右美沙芬和异丙嗪的复方颗粒剂含有活性成分右美沙芬和异丙嗪、抗氧化稳定剂、黏合剂和芳香矫味剂，并采用特殊方法制备，以保证产品的稳定性。处方中每袋含有右美沙芬7.5～30mg、最好为14～16mg；含异丙嗪3.1～12.5mg、最好为5～7mg，右美沙芬和异丙嗪为常用的氢溴酸盐和盐酸盐。抗氧化稳定剂可用亚硫酸氢钠、亚硫酸钠、硫脲、盐酸半胱氨酸、依地酸钙钠、依地酸二钠、抗坏血酸、橘橼酸、苯甲酸钠、橘橼酸钠等，这些稳定剂可单独使用，亦可多种联合应用，用量为处方量的3～24％、最好为14～16％。黏合剂可采用淀粉浆和纤维素类如羧甲纤维素钠、乙基纤维素、羟丙纤维素、羟丙甲纤维素等的混合物，这些黏合剂既可使药物黏合成颗粒，又可在药物表面形成一层膜，对药物起到保护作用。这些黏合剂可单独应用，亦可以不同比例混合应用。制备黏合剂可用水、乙醇和乙醇水溶液。制粒时可采用传统方法用纤维素类黏合剂将全部物料同时制粒，也可分别制粒即先将药物和抗氧化稳定剂以及部分糖粉用纤维素类黏合剂制粒，然后再与其他糖粉的颗粒混匀即可。芳香矫味剂可为蔗糖、甘草酸、甜菊素、糖精钠、橘橼酸、酒石酸、人工合成和天然香料，用量为处方量的90～97％、最好为94～95％，以使制得的颗粒香甜可口，病人乐于接受。
具体实施方式 本发明可用下面的实施例加以说明。
实施例1 处方：
氢溴酸右美沙芬 15g
盐酸异丙嗪 6.25g
维生素C 10g
依地酸二钠 2g
橘橼酸钠 3g
香料 15g
蔗糖粉 936g
EC/HPMC乙醇液 适量
制成 1000袋
制备方法：将氢溴酸右美沙芬、盐酸异丙嗪、维生素C、依地酸二钠、橘橼酸钠、蔗糖细粉混匀，用6％EC/HPMC的乙醇液制成适宜软材，用14目尼龙网制粒，于50℃以下干燥，加入香料，整粒，混合均匀后包装。
实施例2 处方：
氢溴酸右美沙芬 30g
盐酸异丙嗪 12.5g
维生素C 15g
依地酸二钠 5g
橘橼酸 8g
香料 20g
蔗糖粉 1400g
EC/HPMC乙醇液 适量
制成 1000袋
制备方法：将氢溴酸右美沙芬、盐酸异丙嗪、维生素C、依地酸二钠、橘橼酸和少量蔗糖细粉混匀，用EC/HPMC的乙醇液制成适宜软材，用14目尼龙网制粒，于50℃以下干燥制得药物颗粒。另将余下蔗糖粉采用传统方法制粒干燥制得辅料糖粉颗粒。将药物颗粒与辅料糖粉颗粒混合，加入香料，整粒，混合均匀后包装。
Claims (6)
1、右美沙芬和异丙嗪的复方颗粒剂及其制备方法。该颗粒剂含有活性药物、抗氧化稳定剂、黏合剂和芳香矫味剂。特点是通过采用特殊的处方和制备方法，提高了药物的稳定性，从而保证了质量和疗效。
2、权利要求1所述的右美沙芬和异丙嗪的复方颗粒剂剂型及其制备方法。右美沙芬和异丙嗪为常用的氢溴酸盐和盐酸盐。
3、权利要求1所述的颗粒剂每袋含有氢溴酸右美沙芬7.5～30mg、最好为14～16mg；含盐酸异丙嗪3.1～12.5mg、最好为5～7mg。
4、权利要求1所述的抗氧化稳定剂为亚硫酸氢钠、亚硫酸钠、硫脲、盐酸半胱氨酸、依地酸钙钠、依地酸二钠、抗坏血酸、橘橼酸、苯甲酸钠、橘橼酸钠等。这些稳定剂可单独使用，亦可多种联合应用，用量为处方量的3～24％、最好为14～16％。
5、权利要求1所述的黏合剂可采用淀粉浆和纤维素类如羧甲纤维素钠、乙基纤维素、羟丙纤维素、羟丙甲纤维素等的混合物，这些黏合剂既可使药物黏合成颗粒，又可在药物表面形成一层膜，对药物起到保护作用。这些黏合剂可单独应用，亦可以不同比例混合应用，制备黏合剂可用水、乙醇和乙醇水溶液。
6、权利要求1所述的特殊制备方法为采用传统方法用纤维素类黏合剂将全部物料同时制粒，也可分别制粒即先将药物和抗氧化稳定剂以及部分糖粉用纤维素类黏合剂制粒，然后再与其他糖粉的颗粒混匀。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410068920 CN1720918A (zh) | 2004-07-14 | 2004-07-14 | 右美沙芬和异丙嗪的复方颗粒剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410068920 CN1720918A (zh) | 2004-07-14 | 2004-07-14 | 右美沙芬和异丙嗪的复方颗粒剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1720918A true CN1720918A (zh) | 2006-01-18 |
Family
ID=35911754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410068920 Pending CN1720918A (zh) | 2004-07-14 | 2004-07-14 | 右美沙芬和异丙嗪的复方颗粒剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1720918A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922510A (zh) * | 2015-06-01 | 2015-09-23 | 袁志贤 | 一种祛痰平喘药物及其制备方法 |
| CN105250755A (zh) * | 2015-10-19 | 2016-01-20 | 王迁 | 一种中西医治疗支气管炎的药物及其制备方法 |
| CN108096203A (zh) * | 2018-02-09 | 2018-06-01 | 常州康普药业有限公司 | 一种盐酸异丙嗪片及其制备方法 |
-
2004
- 2004-07-14 CN CN 200410068920 patent/CN1720918A/zh active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922510A (zh) * | 2015-06-01 | 2015-09-23 | 袁志贤 | 一种祛痰平喘药物及其制备方法 |
| CN105250755A (zh) * | 2015-10-19 | 2016-01-20 | 王迁 | 一种中西医治疗支气管炎的药物及其制备方法 |
| CN108096203A (zh) * | 2018-02-09 | 2018-06-01 | 常州康普药业有限公司 | 一种盐酸异丙嗪片及其制备方法 |
| CN108096203B (zh) * | 2018-02-09 | 2019-11-12 | 常州康普药业有限公司 | 一种盐酸异丙嗪片及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4365107B2 (ja) | 医薬組成物 | |
| US20200323776A1 (en) | Diclofenac formulations and methods of use | |
| JP5809736B2 (ja) | ロキソプロフェン含有新医薬組成物 | |
| AU2008239683B2 (en) | Melatonin tablet and methods of preparation and use | |
| JP4365106B2 (ja) | 医薬配合剤 | |
| JP2005527508A (ja) | 経口デリバリー用急速溶融多粒子製剤 | |
| CN1720918A (zh) | 右美沙芬和异丙嗪的复方颗粒剂及其制备方法 | |
| CN104739816B (zh) | 包括手性异构化合物的赖葡锌药物组合物及其用途 | |
| JP5571237B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| TW201416072A (zh) | 經安定化的內服用固形製劑 | |
| JP4864369B2 (ja) | チアミン類の安定化方法 | |
| CN104645334B (zh) | N‑乙酰半胱氨酸活性炭组合物及其制备方法和应用 | |
| RU2166937C1 (ru) | Лекарственное средство на основе парацетамола | |
| WO2025046047A1 (en) | Pharmaceutical composition of combination of a non-steroidal anti-inflammatory drugs (nsaids) and decongestant in the form of a powder or granules for preparing a hot drink | |
| CN1616102A (zh) | 治疗感冒的复方干混悬剂及其处方和制备方法 | |
| CN1771915A (zh) | 一种用于治疗儿童感冒的氨酚麻美口腔崩解片及制备方法 | |
| CN1628667A (zh) | 右美沙芬和愈创甘油醚的复方干混悬剂及其制法 | |
| JP2018076312A (ja) | アセトアミノフェン、イソプロピルアンチピリン及びショウガ由来成分を含有する医薬組成物 | |
| CN104415322A (zh) | 谷胱甘肽鸟氨酸盐在制备治疗或预防肝病的药物中的用途 | |
| CN1872055A (zh) | 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法 | |
| CN101732320B (zh) | 一种新的镇咳药用组合物 | |
| JP2024042681A (ja) | ロキソプロフェン又はその塩、および生薬を含有する医薬組成物 | |
| JP2023178260A (ja) | 固形製剤 | |
| CN101756920A (zh) | 以牛蒡苷为活性成分的分散片 | |
| CN1557331A (zh) | 三磷酸胞苷的口服制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |